Transcatheter aortic valve replacement at Bronson has helped hundreds overcome severe aortic stenosis with faster recovery ...

SAN FRANCISCO — After 7 years, transcatheter aortic valve replacement (TAVR) remains equivalent to surgery with respect to durability and safety in low-risk patients, a finding that may blunt ...

Washington, D.C. – May 2, 2025 – New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a strategy of early intervention with ...

CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal of ...

WASHINGTON, DC — Transcatheter aortic valve replacement (TAVR) is superior to surveillance in patients with severe but asymptomatic aortic stenosis with no apparent cost in adverse events, according ...

The Co-STAR trial tested the performance of colchicine in preventing new-onset arrhythmias and subclinical leaflet thrombosis after TAVR. The choice of periprocedural treatment with colchicine was ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. At 7 years, there was no difference in clinical outcomes ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

Transmural Systems’ Telltale guide wire aims to prevent coronary obstruction by modifying the ‘leaflet’ tissue in high-risk patients undergoing TAVR.

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's ...